Baicalein Enhances the Effect of Acarbose on the Improvement of Nonalcoholic Fatty Liver Disease Associated with Prediabetes via the Inhibition of De Novo Lipogenesis

• DOI: 10.1021/acs.jafc.1c04194
• Publication Date: 2021-08-18T14:37:45Z
• Authors: Yan Xing; Xinxiu Ren; Xia Li; Liping Sui; Xuan Shi; Yu Sun; Chunshan Quan; Zhilong Xiu; Yuesheng Dong
• Keywords: Acarbose; Prediabetes; Baicalein; Lipogenesis

Prediabetes is a prevalent metabolic disorder with multiple complications, including nonalcoholic fatty liver disease (NAFLD). In this study, we investigated the combinatorial effect of baicalein, dietary flavonoid abundant in edible plants, and acarbose on prediabetes-associated NAFLD. Baicalein its metabolites inhibited de novo lipogenesis (DNL), thereby decreasing lipid accumulation hepatokine secretion oleic acid-induced hepatocytes. Carbohydrate restriction, which mimicked acarbose, led to comparable results. The baicalein was further verified prediabetic mice Through 16-week intervention, DNL improved glucose tolerance, oxidative stress, histology, secretion, ameliorating insulin resistance Our study demonstrated that enhanced improving NAFLD explored underlying multitarget mechanism, laying theoretical foundation for development supplements simultaneous improvement prediabetes.